BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg]) (clinicaltrials.gov) - Jun 25, 2026 - P4 | N=644 | Not yet recruiting | Sponsor: Chiesi Farmaceutici S.p.A.
New P4 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases
|